GRTS (Gritstone bio) Market Value to Book Value Ratio

Official company branding of Gritstone bio Inc. (GRTS)

The prospects for Gritstone bio, Inc. (GRTS) depend on the pace of personalized drug releases and data regarding solid tumors. This chart of the market cap to book value ratio demonstrates valuation dynamics, where the indicator stands at 0.16. The innovative platform creates a foundation for future payments from pharma behemoths, while a strong staff of bioinformaticians and immunologists, attracted by stock options, guarantees the success of clinical trials.

gritstonebio.com (GRTS): Capitalization to Book Value Ratio from 07/04/2022 to 11/02/2024
Brand item of gritstonebio.com

For Gritstone bio, Inc. (GRTS), the chart of the market capitalization to net asset ratio reflects a critical discrepancy between the exchange price and the actual value of resources. This metric is calculated by dividing the market capitalization by the value of equity, which allows for the determination of the degree of asset overvaluation or the level of discount. Amid bankruptcy and a shrinking R&D pipeline, this indicator reveals the speculative nature of the quotes. It is essential for investors to correlate this data with the risks of underfunding anti-cancer developments.

Competitor analysis

ImmunityBio, Inc. - Market Value to Book Value Ratio|IMCR (immunocore.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio JANX (Janux Therapeutics, Inc.)|Market-to-Book Ratio RCUS|Market Value to Book Value Ratio Zymeworks Corp ZYME|Capitalization to Book Value Ratio Tango Therapeutics Corp (TNGX)|Iovance Biotherapeutics - Market Capitalization to Book Value Ratio|immatics.com - Market Cap to Net Assets Ratio|XNCR (Xencor) - Market Value to Book Value Ratio|CMPX: Market-to-Book Ratio|Replimune Corp (REPL) - Market Value to Book Value Ratio|LYEL (Lyell Pharma) - Market Value to Book Value Ratio|Market Value to Book Value Ratio IPHA (Innate Pharma S.A.)|Market-to-Book Ratio Pyxis|CGEN: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio IO Biotech Inc IOBT|STRO: Market Cap to Net Assets Ratio|INKT - Market-to-Book Ratio|Market Cap to Net Assets Ratio Werewolf (HOWL)|IMMX - Market Value to Book Value|ALX Oncology - Market Capitalization to Book Value Ratio|CUE (Cue Biopharma Inc.) - Market Capitalization to Book Value|Market Value to Book Value Ratio PDSB|Market Cap to Net Assets Ratio SONN|Market Value to Book Value Ratio MAIA (MAIA Biotechnology)|Market Cap to Net Assets Ratio liminatuspharma.com LIMN|Market Cap to Net Assets Ratio LVTX (LAVA Therapeutics)|NextCure Inc - Market Capitalization to Book Value Ratio|Leap Tx (LPTX) - Market Value to Book Value Ratio|INTS: Capitalization to Book Value Ratio|Market Value to Book Value Ratio SNSE|Market-to-Book Ratio therivabio.com|Kineta - Market Cap to Net Assets Ratio|Market Value to Equity Ratio NexImmune Inc (NEXI)|Market Cap to Net Assets Ratio Turnstone Biologics|Market Cap to Book Value Multiple Vaccinex Inc (VCNX)|Market Capitalization to Book Value Ratio Harpoon Therapeutics